Business Wire

SBC Medical Appoints Dr. Steven R. Cohen as Medical Strategy Advisor to Accelerate Global Expansion

Share

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the appointment of Dr. Steven R. Cohen, a globally recognized leader in plastic and craniofacial surgery, as Medical Strategy Advisor. His appointment marks a significant step in the company’s strategy to expand its global footprint and enhance its medical excellence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714547888/en/

Dr. Cohen

Dr. Cohen is the Founder of Faces+, an advanced aesthetic and reconstructive surgery center in San Diego, California. With over 30 years of clinical experience, he is widely known for his pioneering work in regenerative aesthetics, including the clinical application of fat-derived stem cells, skeletal facial aesthetic surgery, and the integration of artificial intelligence into medical innovation. Dr. Cohen is also the inventor of the internal craniofacial distraction device and LipoCube, both of which have become global standards in the field.

Recognized by Newsweek as one of “America’s Best Plastic Surgeons,” Dr. Cohen has authored numerous scientific publications and textbooks and is a sought-after speaker at international conferences. He is also a Clinical Professor at the University of California, San Diego, and an active member of several global societies, including the American Society of Plastic Surgeons (ASPS).

Following its Nasdaq listing in September 2024, SBC Medical has accelerated its global growth initiatives. With Dr. Cohen’s participation, the company aims to elevate its medical quality, strengthen brand positioning in international markets, expand academic collaborations, and enhance its physician training programs—further solidifying its presence as a truly global medical group.

Message from Yoshiyuki Aikawa, CEO of SBC Medical
“It is a great honor to welcome Dr. Steven R. Cohen, a world-class clinician, to our team. His deep expertise and global perspective will play a transformative role in elevating our medical standards, physician education, and brand development. We look forward to his contributions as we enter a new phase of growth.”

Message from Dr. Steven R. Cohen
“I am honored to join SBC Medical, a company that is not only expanding rapidly but also committed to innovation and patient-centered care. SBC Medical’s investment in physician education and international collaboration resonates deeply with my own values. I look forward to contributing to the advancement of safer, scientifically grounded, and aesthetically refined regenerative aesthetics on a global scale.”

About Dr. Steven R. Cohen (Partial Profile)

  • Board-certified in Plastic Surgery and Craniofacial Surgery
  • Founder and Medical Director, Faces+ (San Diego, California)
  • Clinical Professor of Plastic Surgery, University of California, San Diego
  • Inventor of the internal craniofacial distraction device and LipoCube
  • Recognized as one of America’s Best Plastic Surgeons by Newsweek
  • Global authority in facial reconstruction, stem cell therapy, and 3D surgical simulation
  • Frequent keynote speaker at international academic societies; author of multiple books and peer-reviewed articles

For more information about Dr. Steven R. Cohen, please visit: https://www.facesplus.com/about/dr-steven-r-cohen/

About SBC Medical

SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensing of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics.

For more information, visit https://sbc-holdings.com/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250714547888/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis15.7.2025 01:01:00 CEST | Press release

- All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine. This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We’re proud that ALYFTREK®, our fifth CF medicine, is available today as another treatment option for all eligible CF patients in England. It represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease,” said Lud

SES Receives All Required Regulatory Approvals to Complete Intelsat Acquisition14.7.2025 22:15:00 CEST | Press release

SES received the final regulatory approvals for the SES-Intelsat transaction, including the US Federal Communications Commission. On 30 April 2024, SES and Intelsat announced an agreement for SES to acquire Intelsat for a cash consideration of $3.1 billion (€2.8 billion). The transaction was subject to receipt of relevant regulatory clearances and other relevant requirements which all have now been obtained. As a result, SES plans to close the transaction on or about Thursday, 17 July 2025. Once closing has occurred, a press release will be published to confirm that the transaction has successfully closed. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and ope

Loomis Sayles Celebrates 15 Years of Growth Equity Strategies Team Under Leadership of Aziz V. Hamzaogullari14.7.2025 22:05:00 CEST | Press release

Loomis, Sayles & Company: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714614048/en/ 90.7 160 1 BILLION IN ASSETS UNDER MANAGEMENT COMBINED YEARS OF INVESTMENT EXPERIENCE INVESTMENT PHILOSOPHY GES Team As of 5/31/2025 GES Team As of 5/31/2025 Supported by a seven-step research framework Loomis, Sayles & Company proudly celebrates the 15-year anniversary of a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. GES is a cohesive team with nearly 19 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to nearly $91 billion as of 31 Ma

Cessna Skyhawk Soars With Enhanced Efficiency: Solid-State Dual Electronic Ignition System Introduced to the Industry-leading Piston14.7.2025 18:00:00 CEST | Press release

The industry-leading training aircraft, the Cessna Skyhawk, now features a dual electronic ignition system (dual EIS), enhancing maintenance, efficiency and overall operation of the single-engine, high-wing piston. The dual Lycoming electronic ignition system is now standard on all new Cessna Skyhawk aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714759359/en/ Cessna Skyhawk soars with enhanced efficiency: solid-state dual electronic ignition system introduced to the industry-leading piston (Photo Credit: Textron Aviation) The Cessna Skyhawk is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The dual EIS replaces the previous dual magneto ignition system on the Skyhawk, incorporating advanced electronic components and reducing the number of internal moving parts to optimize operation. This solid-state electronic technology improves maintenance intervals, fuel efficiency and en

The 2025 Empire State Building Run-Up Returns Oct. 814.7.2025 17:48:00 CEST | Press release

Presented by NYU Langone Health and Powered by the Challenged Athletes FoundationLottery Opens July 14 The Empire State Building (ESB) announced today general lottery registration for the annual Empire State Building Run-Up (ESBRU) on Oct. 8, 2025, at 8 p.m. ESB also announced the ESBRU will be presented by NYU Langone Health and powered by the Challenged Athlete’s Foundation. General lottery registration will be open from July 14 through July 28, 2025. In the 47th annual Run-Up, 225 runners will race up the iconic building’s 1,576 stairs to the world-famous Observatory. This year’s heats will include elite men and women, media, celebrities, New York City real estate brokers, building tenants, CAF athletes, members of the NYPD and FDNY, and the public, among others. On July 30, registered runners will be notified of their race status with participation costs of $175 per runner to be charged only upon acceptance from the lottery. “We are delighted to welcome NYU Langone Health as our ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye